QuantX Biosciences raised $85M Series B venture round, led by Lilly Asia Ventures.
Get email updates
QuantX Biosciences, a leading biotechnology company based in Princeton, New Jersey, specializing in computational drug discovery and small-molecule therapeutic products, recently announced the successful close of its Series B funding round, raising an impressive $85 million. This significant investment will accelerate the company's innovative research and development initiatives, further advancing its mission to bring transformative small-molecule therapeutics to patients worldwide. The funding underscores strong investor confidence in QuantX's proprietary computational platforms and its promising pipeline of novel drug candidates.
| Investor | Firm Type | Partner |
|---|---|---|
| Venture Capital | — | |
Sanofi VenturesLEAD | Venture Capital | — |
| Venture Capital | — |
This company has completed 1 funding round. Current round is highlighted.
Total Raised
$85M
Top Valuation
-
QuantX Biosciences is a biotechnology company based in Princeton, New Jersey, specializing in computational drug discovery and the development of small-molecule therapeutic products.
QuantX Biosciences successfully raised $85 million in its recent Series B funding round.
The $85 million in Series B funding will be used to accelerate the company's research and development initiatives, enhance its computational drug discovery platforms, and advance its pipeline of small-molecule therapeutic products.
QuantX Biosciences is located in Princeton, New Jersey, United States, North America.
QuantX Biosciences is at the forefront of the biotechnology sector, leveraging advanced computational approaches to revolutionize drug discovery. Headquartered in Princeton, New Jersey, the company focuses on identifying and developing novel small-molecule therapeutic products with high precision and efficiency, addressing critical unmet medical needs across various disease areas.
The successful Series B funding round, securing $85 million, marks a pivotal moment for QuantX Biosciences. This substantial capital injection will be strategically deployed to expand the company's research and development capabilities, enhance its computational infrastructure, and accelerate preclinical and clinical development of its lead drug candidates. The funding round attracted a diverse group of prominent investors, reflecting widespread confidence in QuantX's scientific expertise and market potential.
With this new funding, QuantX Biosciences is poised to significantly expedite the progression of its small-molecule therapeutic pipeline. The company's unique computational platform enables the rapid identification and optimization of drug candidates, offering a distinct advantage in the competitive pharmaceutical landscape. This acceleration will bring innovative treatments closer to patients who stand to benefit most.
Operating from its strategic location in Princeton, New Jersey, QuantX Biosciences is poised for significant growth and impact within the North American and global biotechnology markets. The new funding will support the recruitment of top-tier scientific talent, foster collaborations with leading academic institutions and industry partners, and strengthen the company's position as a leader in computational drug discovery. This expansion solidifies New Jersey's role as a hub for groundbreaking biotechnological advancements.